Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96F44
UPID:
TRI11_HUMAN
Alternative names:
Protein BIA1; RING finger protein 92; Tripartite motif-containing protein 11
Alternative UPACC:
Q96F44; A6NKE2; B2RB82; B3KUS3; B4DX88; Q5VSU1; Q8NCA6; Q9C022
Background:
E3 ubiquitin-protein ligase TRIM11, also known as Protein BIA1 and RING finger protein 92, plays a crucial role in cellular processes by promoting the degradation of insoluble ubiquitinated proteins. It is involved in modulating cortical neurogenesis through the ubiquitination and subsequent proteasomal degradation of PAX6, and regulates the intracellular level of humanin or HN-containing proteins. TRIM11's antiviral activity, particularly against HIV-1 and murine leukemia virus, is attributed to its ability to suppress viral gene expression through a functional E3 ubiquitin-protein ligase domain.
Therapeutic significance:
Understanding the role of E3 ubiquitin-protein ligase TRIM11 could open doors to potential therapeutic strategies.